Biogen (BIIB) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $2.62
- Estimate
- $1.99
- Surprise
- +31.5%
- Revenue (period 2026-09-30)
- $2.80B
- Score at report (before → after)
- 5.2 → 5.4/10
Revenue source: xbrl.
How the report landed
Biogen (BIIB) beat the $1.99 estimate with adjusted EPS of $2.62 — a large 31.5% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.2/10) to Hold at 5.4/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates BIIB Hold at 5.4/10.
4 of the last 4 quarters beat the estimate; this quarter's +31.5% surprise compares with a +38.9% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Analyst target reached - limited upside remaining
- Weak growth
- Target reached (-4.2% upside)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $244.05
- Stop
- $228.09
The stock trades at 43.3× trailing but 14.8× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 71 — a level conventionally read as overbought; gains at these levels often lean on momentum; trading volume is running 1.9× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
BIIB at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - General
- Market cap
- $36.06B
- P/E (fwd)
- 14.8
- P/E (ttm)
- 43.3
- 52-week range
- $138.00–$258.78
- Off 52-week high
- 5.7%
- RSI (14)
- 71
- Volume vs avg
- 1.85×
- Score today
- 5.4/10